The forward P/E of 23.5x is only modestly below the trailing multiple, suggesting investors are pricing in a recovery from the recent EPS miss. However, with TTM revenue growth at just 1.4%, the multiple implies that profitability, not growth, will drive returns. The EV/EBITDA of 16.0x is in line with PG's 17.0x but above UL's 14.1x, indicating the market still awards a staples-plus premium for CL's pet and professional oral care mix. If operating margin compression persists, the multiple could contract toward the sector average.

The 60%+ gross margin reflects strong pricing power and a premium product mix, particularly in Hill's and professional oral care. However, the 210 basis point operating margin contraction in 2026Q2, despite a 4.9% revenue increase, indicates that overhead costs are growing faster than gross profit. This negative operating leverage suggests that the company's cost discipline is being tested, and investors should monitor whether SG&A growth moderates in coming quarters. The net margin of 12.9% remains respectable but is below the 14.5% seen a year ago, reflecting the EPS miss.

ROIC's stability at roughly 10-12% indicates that the underlying business continues to generate consistent returns on invested capital, driven by high margins and moderate asset turnover. In contrast, ROE is distorted by the near-zero equity base, making it an unreliable measure of performance. The 2025Q4 ROE of -4.6% and the 2026Q2 ROE of 131.7% highlight how share repurchases have amplified equity volatility. Investors should focus on ROIC as the more meaningful metric, as it reflects the true earning power of the operating assets.

The CCC of 34 days is still efficient for a consumer staples company, but the sequential increase suggests that inventory is building (DIO rose to 94 days) while payables have not expanded proportionately. DSO of 33 days is stable, indicating no deterioration in receivables quality. The slight lengthening of the cycle may reflect seasonal inventory builds or supply chain disruptions, but it warrants monitoring for signs of channel stuffing in emerging markets. Asset turnover remains low at 0.32x, consistent with a capital-intensive manufacturing model, but the company's high margins compensate for this.

The dramatic rise in D/E is primarily due to the collapse in total equity to just $236M, not a significant increase in debt. With total debt near $8B, the company's leverage is extreme on a book basis, but interest coverage of 16.3x suggests that operating income comfortably covers interest expense. However, the thin equity base could trigger covenant concerns or restrict financial flexibility. The D/EBITDA ratio of 6.7x is elevated relative to peers like PG at 0.63x, but CL's stable cash flows mitigate refinancing risk. Investors should monitor whether the company reduces buybacks to rebuild equity.

The current ratio above 1.0 provides a modest cushion, but the quick ratio below 0.7 suggests that if inventory becomes illiquid, the company could face short-term funding stress. Cash of $1.4B and strong operating cash flow (FCF margin of 16.2%) provide a buffer, but the thin liquidity position leaves little room for error. In a severe downturn, CL would likely rely on its credit facilities or reduce buybacks to preserve cash. The stable cash conversion cycle and low capital intensity support liquidity, but the negative equity base remains a structural vulnerability.

CL's valuation premium is justified by its higher gross margin (61.5% vs. PG's ~50%) and its exposure to faster-growing pet nutrition, but its ROIC is below that of PG and KMB, indicating less efficient capital deployment. The D/E ratio of 13.88 is far above peers, reflecting the equity erosion rather than operational distress. The market appears to be pricing CL as a consumer health company rather than a traditional household products firm, which may be optimistic if margin compression continues. Investors should compare CL's multiple to HLN and GIS for a more accurate assessment of its pet and oral care businesses.